Prevalence of drug-drug interactions in cancer patients treated with anti-cancer drugs.
- Conditions
- Cancer, chemotherapy, drug-drug interactions, oncology, pharmacology, risk factors.
- Registration Number
- NL-OMON22087
- Lead Sponsor
- Erasmus University Medical Center
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
All ambulatory patients with the diagnosis of a solid tumour or a haematological malignancy, who are receiving one or more (oral) anti-cancer therapies, are included in the study.
Exclusion Criteria
1. The use of experimental trial agents;
2. Age <18 years;
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of drug-drug interactions (DDI's) and the clinical consequence of these DDI's.
- Secondary Outcome Measures
Name Time Method The secondary objective is to obtain more insight into possible determinants for the occurrence of these DDIs.